| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8232280 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 6 Pages |
Abstract
These preliminary results suggest that sunitinib and helical tomotherapy yield high Response Evaluation Criteria in Solid Tumors (RECIST) and AFP response rates in advanced HCC with an acceptable safety profile. Maintenance sunitinib after RT potentially prolongs survival. A randomized trial is warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Kwan-Hwa M.D., Chao-Sheng M.D., Ph.D., Chih-Chia M.D., Hui-Ling M.D., M.Sc., Yuk-Wah M.D., Kuo-Ching M.D., Minesh P. M.D.,